| FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment |
PARAMUS, N.J. , May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. |
prnewswire.com |
2025-05-14 11:13:00 |
Czytaj oryginał (ang.) |
| REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript |
REGENXBIO Inc. (NASDAQ:RGNX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & CEO Steve Pakola - Chief Medical Officer Mitch Chan - CFO Conference Call Participants Mani Foroohar - Leerink Partners Gena Wang - Barclays Judah Frommer - Morgan Stanley Annabel Samimy - Stifel Paul Choi - Goldman Sachs Sean McCutcheon - Raymond James Eduardo Martinez-Montes - H.C. Wainwright Operator Welcome, everyone to the First Quarter 2025 REGENXBIO Earnings Conference Call. |
seekingalpha.com |
2025-05-13 11:07:43 |
Czytaj oryginał (ang.) |
| REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II |
FDA assigns PDUFA target action date of November 9, 2025 RGX-121 on track to be the first gene therapy and one-time treatment for MPS II Partner Nippon Shinyaku to lead commercialization upon potential approval REGENXBIO to lead commercial manufacturing and supply chain ROCKVILLE, Md. , May 13, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for clemidsogene lanparvovec (RGX-121) for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome. |
prnewswire.com |
2025-05-13 11:05:00 |
Czytaj oryginał (ang.) |
| Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates |
Regenxbio (RGNX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to loss of $1.38 per share a year ago. |
zacks.com |
2025-05-12 22:30:55 |
Czytaj oryginał (ang.) |
| REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights |
RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025 Additional Phase I/II functional data expected 1H 2025 Initiating commercial supply manufacturing in Q3 2025 FDA acceptance of Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121, partnered with Nippon Shinyaku) expected in May 2025 Pivotal data evaluating the safety and efficacy of the subretinal delivery of surabgene lomparvovec (ABBV-RGX-314, partnered with AbbVie) in patients with wet age-related macular degeneration are expected in 2026 and planning of diabetic retinopathy pivotal study continues Conference call today at 4:30 p.m. ET ROCKVILLE, Md. |
prnewswire.com |
2025-05-12 20:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting |
ROCKVILLE, Md. , May 8, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans, May 13 through 17, 2025. |
prnewswire.com |
2025-05-08 11:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO to Participate in Upcoming Investor Conferences |
ROCKVILLE, Md. , May 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: BofA Securities Health Care Conference 2025 Presentation: Tuesday, May 13, 2025 at 5:00 p.m. |
prnewswire.com |
2025-05-06 11:05:00 |
Czytaj oryginał (ang.) |
| Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release |
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-05 15:05:41 |
Czytaj oryginał (ang.) |
| REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights |
ROCKVILLE, Md. , April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m. |
prnewswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| 5 Reasons To Buy Regenxbio Right Now |
Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, with potential for the EV to turn negative once upcoming scheduled/milestone payments and royalties come in. RGNX benefits from strategic partnerships, including $110M from Nippon Shinyaku and $200M from AbbVie, plus potential higher royalties from Novartis. |
seekingalpha.com |
2025-03-26 14:31:18 |
Czytaj oryginał (ang.) |
| REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY |
Positive biomarker data in patient aged 1-3 add to consistent, robust microdystrophin and transduction levels across all treated ages Patient aged 3 years at dosing had expression level at 122.3% compared to control With a differentiated novel construct and proactive short course immune modulation regimen, RGX-202 continues to demonstrate encouraging safety profile with no SAEs or AESIs Phase III portion of AFFINITY DUCHENNE® trial enrolling ambulatory patients aged 1 and above, on track for BLA submission mid-2026 ROCKVILLE, Md. , March 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated investigational gene therapy for Duchenne muscular dystrophy (Duchenne). |
prnewswire.com |
2025-03-19 11:15:00 |
Czytaj oryginał (ang.) |
| REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript |
REGENXBIO Inc. (NASDAQ:RGNX ) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & Chief Executive Officer Steve Pakola - Chief Medical Officer Mitch Chan - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley Gena Wang - Barclays Annabel Samimy - Stifel Brian Skorney - Baird Paul Choi - Goldman Sachs Ellie Merle - UBS Sean McCutcheon - Raymond James Alec Stranahan - Bank of America Yi Chen - H.C. Wainwright & Company Operator Welcome everyone to the Fourth Quarter and Year End 2024 REGENXBIO Earnings Conference Call. |
seekingalpha.com |
2025-03-13 20:44:49 |
Czytaj oryginał (ang.) |
| Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates |
Regenxbio (RGNX) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago. |
zacks.com |
2025-03-13 20:25:25 |
Czytaj oryginał (ang.) |
| REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates |
Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with Nippon Shinyaku aims to expand potential access and commercial opportunity in MPS II and MPS I Pivotal trial of RGX-202 for Duchenne Muscular Dystrophy progressing rapidly; enrollment completion expected in 2025 with BLA filing in mid-2026 AbbVie-partnered retinal franchise continues advancing; pivotal data evaluating the safety and efficacy of the subretinal delivery of surabgene lomparvovec (ABBV-RGX-314) in patients with wet age-related macular degeneration are expected in 2026 and planning of diabetic retinopathy pivotal study continues Conference call today at 4:30 p.m. ET ROCKVILLE, Md. |
prnewswire.com |
2025-03-13 18:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference |
ROCKVILLE, Md. , March 10, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202 for the treatment of Duchenne muscular dystrophy will be presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place in Dallas, TX, March 16-19, 2025. |
prnewswire.com |
2025-03-10 09:05:00 |
Czytaj oryginał (ang.) |
| Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know |
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-03-06 13:05:31 |
Czytaj oryginał (ang.) |
| REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases |
ROCKVILLE, Md. , March 4, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced strategic partnership with Nippon Shinyaku. |
prnewswire.com |
2025-03-04 09:31:00 |
Czytaj oryginał (ang.) |
| REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights |
ROCKVILLE, Md. , Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. |
prnewswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO to Participate in Upcoming Investor Conferences |
ROCKVILLE, Md. , Feb. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: TD Cowen's 45th Annual Health Care Conference Fireside Chat: Wednesday, March 5 at 1:10pm ET Location: Boston, MA Leerink Partners Global Healthcare Conference Fireside Chat: Tuesday, March 11 at 9:20am ET Location: Miami, FL Barclays 27th Annual Global Healthcare Conference Fireside Chat: Wednesday, March 12 at 3:30pm ET Location: Miami, FL UBS Virtual CNS Day Fireside Chat: Monday, March 17 at 10:00am ET Location: Virtual RBC Inaugural Virtual Ophthalmology Conference Fireside Chat: April 3 at 8:15am ET Location: Virtual Live webcasts of select fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. |
prnewswire.com |
2025-02-25 18:05:00 |
Czytaj oryginał (ang.) |
| Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns |
Goldman Sachs downgraded Regenxbio Inc RGNX, citing gene therapy's appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offer longer-lasting effects at lower costs. |
benzinga.com |
2025-02-11 17:20:40 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet |
The consensus price target hints at a 333% upside potential for Regenxbio (RGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-02-10 12:56:15 |
Czytaj oryginał (ang.) |
| REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 |
ROCKVILLE, Md. , Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 21st Annual WORLDSymposium™ 2025, taking place in San Diego, CA February 3-7, 2025. |
prnewswire.com |
2025-01-30 09:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High? |
The mean of analysts' price targets for Regenxbio (RGNX) points to a 357.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-01-24 12:55:18 |
Czytaj oryginał (ang.) |
| Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026 |
Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025. Partnership established with Nippon Shinyaku to develop RGX-121 and RGX-111 for the treatment of patients with MPS II and MPS I respectively. Data from both the ASCENT and ATMOSPHERE pivotal studies, using ABBV-RGX-314 for the treatment of patients with Wet Age-Related Macular Degeneration, expected in 2026. |
seekingalpha.com |
2025-01-16 06:01:10 |
Czytaj oryginał (ang.) |
| Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again |
Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets wet AMD with global regulatory submissions expected in H1 2026; RGX-121 has a rolling BLA submission expected to complete in Q1 2025. Financially, RGNX has a market cap of $344mn and a cash balance of $279mn, bolstered by a recent $110mn upfront fee from Nippon Shinyaku. |
seekingalpha.com |
2025-01-15 17:27:58 |
Czytaj oryginał (ang.) |
| REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases |
REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing Nippon Shinyaku to lead commercialization of first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis I (MPS I) in U.S. and Asia REGENXBIO retains rights to RGX-121 Priority Review Voucher (PRV) with potential accelerated approval expected in 2025; rolling BLA submission underway ROCKVILLE, Md. , Jan. 14, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. |
prnewswire.com |
2025-01-14 07:00:00 |
Czytaj oryginał (ang.) |
| AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program |
Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) NORTH CHICAGO, Ill. and ROCKVILLE, Md. |
prnewswire.com |
2025-01-13 10:31:00 |
Czytaj oryginał (ang.) |
| Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 |
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. |
prnewswire.com |
2024-12-06 20:29:00 |
Czytaj oryginał (ang.) |
| REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA |
Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above with first patient dosed Phase I/II data show RGX-202 recipients exceeding external natural history and established benchmarks for clinical outcomes Functional improvements seen in all patients treated with dose level 1 and dose level 2 at 12 and 9 months respectively New biomarker data confirms consistent robust expression of differentiated RGX-202 microdystrophin in the muscle Favorable safety profile observed at both dose levels; no serious adverse events or AEs of special interest Webcast to be held at 8:00 a.m. today ROCKVILLE, Md. |
prnewswire.com |
2024-11-18 09:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 |
- Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md. |
prnewswire.com |
2024-11-14 09:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript |
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-07 01:16:13 |
Czytaj oryginał (ang.) |
| Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates |
Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago. |
zacks.com |
2024-11-06 21:00:45 |
Czytaj oryginał (ang.) |
| REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates |
Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this month BLA submission for RGX-121 initiated and expected to complete in Q1 2025 Positive Phase II data support bilateral administration of subretinal ABBV-RGX-314; data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile End-of-Phase II meeting for ABBV-RGX-314 in diabetic retinopathy accelerated to Q4 2024 to support global pivotal program initiation in H1 2025 Conference call today at 4:30 p.m. ET ROCKVILLE, Md. |
prnewswire.com |
2024-11-06 18:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO to Participate in Upcoming Investor Conferences |
ROCKVILLE, Md. , Nov. 4, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: UBS Global Healthcare Conference Fireside Chat: Wednesday, November 13 at 12:30 p.m. |
prnewswire.com |
2024-11-04 09:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track |
Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected any day now in Q4 of 2024. The global Hunter Syndrome treatment market is expected to reach $1.78 billion by 2030. |
seekingalpha.com |
2024-10-31 17:38:10 |
Czytaj oryginał (ang.) |
| REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights |
ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m. |
prnewswire.com |
2024-10-30 09:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 |
97% reduction in treatment burden at nine months after treatment with ABBV-RGX-314 Data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile Well tolerated with zero cases of intraocular inflammation in a setting of no prophylactic steroids Data highlight the potential of ABBV-RGX-314 to treat both eyes in wet AMD ROCKVILLE, Md. , Oct. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD). |
prnewswire.com |
2024-10-21 11:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting |
ROCKVILLE, Md. , Oct. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present new interim data evaluating subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) at the American Academy of Ophthalmology 2024 annual meeting. |
prnewswire.com |
2024-10-18 11:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference |
ROCKVILLE, Md. , Sept. 23, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines Conference on Monday, September 30, 2024. |
prnewswire.com |
2024-09-23 20:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO Appoints Mitchell Chan as Chief Financial Officer |
Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programs Vit Vasista steps down following more than 15 years at the Company ROCKVILLE, Md. , Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. |
prnewswire.com |
2024-09-17 11:05:00 |
Czytaj oryginał (ang.) |
| Goldman Sachs Recommends These 3 Growth Stocks As Strong Buys in September |
Among the Wall Street firms investors often pay closest attention to, Goldman Sachs (NYSE:GS) has to be atop the list. |
247wallst.com |
2024-09-09 12:29:12 |
Czytaj oryginał (ang.) |
| REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect |
- Data from pivotal dose level demonstrates long-term, sustained reductions in CSF levels of HS D2S6, a key biomarker of brain disease in MPS II - 80% of patients who received the pivotal dose discontinued intravenous enzyme replacement therapy or remained treatment-naïve - Submission of a rolling BLA using the accelerated approval pathway on track for Q3 2024 ROCKVILLE, Md. , Sept. 3, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of patients with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. |
prnewswire.com |
2024-09-03 12:04:00 |
Czytaj oryginał (ang.) |
| REGENXBIO to Participate in Upcoming Investor Conferences |
ROCKVILLE, Md. , Aug. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside Chat: Thursday, September 5, 2024 at 5:35 p.m. |
prnewswire.com |
2024-08-29 20:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium |
ROCKVILLE, Md. , Aug. 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the SSIEM 2024 Annual Symposium, taking place in Porto, Portugal from September 3-6, 2024. |
prnewswire.com |
2024-08-27 11:05:00 |
Czytaj oryginał (ang.) |
| REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference |
ROCKVILLE, Md. , Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C. |
prnewswire.com |
2024-08-08 11:05:00 |
Czytaj oryginał (ang.) |
| 7 Biotech Stocks to Buy for Their Game-Changing Potential |
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one. |
investorplace.com |
2024-08-08 10:00:00 |
Czytaj oryginał (ang.) |
| Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder |
Regenxbio Inc.'s rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected in Q3 of 2024. Additional results from the phase 1/2/3 CAMPSIITE study, using RGX-121 for the treatment of patients with MPS II, expected in the 2nd half of 2024. Initiation of a pivotal study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q4 of 2024. |
seekingalpha.com |
2024-08-06 20:03:56 |
Czytaj oryginał (ang.) |